In brief
The Food and Drug Administration has approved a new generic version of mifepristone, an abortion pill used to terminate pregnancies up to 10 weeks. This decision has faced criticism from anti-abortion advocates, particularly from organizations associated with the former Trump administration, who regard the approval as misguided. The FDA has historically deemed mifepristone safe, and its accessibility has been further increased under recent regulations, yet ongoing state-level restrictions complicate access across the U.S.
Federal officials have greenlighted the approval of another generic formulation of the abortion pill mifepristone, which quickly ignited criticism from anti-abortion factions connected to the Trump administration.
Evita Solutions, the drug manufacturer, confirmed the FDA's approval on its platform, highlighting that this version of mifepristone is sanctioned for terminating pregnancies within the first 10 weeks.
Students for Life Action, a prominent anti-abortion organization, labeled the approval as “a stain on the Trump presidency” and asserted that the FDA must be scrutinized. This reaction arises as pressure mounts on Republican health officials to reconsider the 25-year-old approval of mifepristone, despite its long-standing recognition as a safe and effective option by FDA scientists.
The FDA had initially approved mifepristone in the year 2000, and since then, access to the drug has been progressively relaxed, allowing for the introduction of a generic variant in 2019 from GenBioPro.
In a recent communication to Republican state attorneys general, FDA Commissioner Dr. Marty Makary and Health Secretary Robert F. Kennedy Jr. committed to undertaking a thorough review of the drug’s safety.
Despite the generic approval, the accessibility of mifepristone remains fraught with obstacles. State laws imposing bans on abortion and associated restrictions are challenging the drug’s availability, which has mostly been met with resistance from major medical associations such as the American Medical Association. Legal battles continue to shape the landscape surrounding mifepristone’s use effectively.
As the FDA usually approves generic drugs as a standard practice, it is noteworthy that Evita Solutions had initiated its application to sell this drug four years before this recent approval. Public inquiries about the company's statements regarding its commitment to affordable and compassionate abortion care have yet to elicit a response.
